Plerixafor: a review of its use in stem-cell mobilization in patients with lymphoma or multiple myeloma
GM Keating - Drugs, 2011 - Springer
Plerixafor (Mozobil®) is a CXCR4 chemokine receptor antagonist that is indicated for use in
combination with granulocyte colony-stimulating factor (G-CSF) to mobilize stem cells to the …
combination with granulocyte colony-stimulating factor (G-CSF) to mobilize stem cells to the …
Imaging CXCR4 receptors expression for staging multiple myeloma by using 68Ga-Pentixafor PET/CT: comparison with 18F-FDG PET/CT
AS Shekhawat, B Singh, P Malhotra… - The British Journal of …, 2022 - academic.oup.com
Objectives: 68Ga-Pentixafor positron emission tomography (PET) imaging targets CXCR4
expression which is overexpressed in multiple myeloma (MM). In this study, we evaluated …
expression which is overexpressed in multiple myeloma (MM). In this study, we evaluated …
Preemptive use of plerixafor in difficult‐to‐mobilize patients: an emerging concept
E Jantunen, RM Lemoli - Transfusion, 2012 - Wiley Online Library
Mobilized peripheral blood (PB) is the preferred source of stem cells (PBSCs) for autologous
stem cell transplantation (ASCT). The use of cytokines, alone or in combination with …
stem cell transplantation (ASCT). The use of cytokines, alone or in combination with …
European data on stem cell mobilization with plerixafor in non-Hodgkin's lymphoma, Hodgkin's lymphoma and multiple myeloma patients. A subgroup analysis of the …
K Hübel, MM Fresen, JF Apperley, GW Basak… - Bone marrow …, 2012 - nature.com
The effectiveness of the novel hematopoietic stem cell mobilizing agent plerixafor was
evaluated in nationwide compassionate use programs in 13 European countries. A total of …
evaluated in nationwide compassionate use programs in 13 European countries. A total of …
Hematopoietic stem cell mobilization for gene therapy of adult patients with severe β-thalassemia: results of clinical trials using G-CSF or plerixafor in splenectomized …
E Yannaki, T Papayannopoulou, E Jonlin, F Zervou… - Molecular Therapy, 2012 - cell.com
The safety and efficacy of hematopoietic stem cell (HSC) mobilization was investigated in
adult splenectomized (SPL) and non-SPL patients with thalassemia major, in two clinical …
adult splenectomized (SPL) and non-SPL patients with thalassemia major, in two clinical …
Plerixafor as preemptive strategy results in high success rates in autologous stem cell mobilization failure
N Worel, G Fritsch, H Agis, A Böhm… - Journal of Clinical …, 2017 - Wiley Online Library
Plerixafor in combination with granulocyte‐colony stimulating factor (G‐CSF) is approved for
autologous stem cell mobilization in poor mobilizing patients with multiple myeloma or …
autologous stem cell mobilization in poor mobilizing patients with multiple myeloma or …
Haematopoietic stem cell mobilization with plerixafor and G‐CSF in patients with multiple myeloma transplanted with autologous stem cells
GW Basak, O Jaksic, Z Koristek… - European journal of …, 2011 - Wiley Online Library
A proportion of patients with multiple myeloma (MM) who have already undergone
autologous stem cell transplantation (autoSCT) might benefit from a further transplantation …
autologous stem cell transplantation (autoSCT) might benefit from a further transplantation …
Plerixafor for autologous stem-cell mobilization and transplantation for patients in Ontario
CT Kouroukis, NP Varela, C Bredeson… - Current …, 2016 - pmc.ncbi.nlm.nih.gov
Background High-dose chemotherapy with autologous stem-cell transplantation (asct) is an
accepted part of standard therapy for patients with hematologic malignancies. Usually, stem …
accepted part of standard therapy for patients with hematologic malignancies. Usually, stem …
Plerixafor injection: a hematopoietic stem cell mobilizer in non-Hodgkin lymphoma and multiple myeloma
E Jantunen, V Varmavuo, J Valtola - Expert review of hematology, 2016 - Taylor & Francis
Introduction: A combination of granulocyte colony-stimulating factor (G-CSF) and
chemotherapy or G-CSF alone are the most common mobilization regimens for …
chemotherapy or G-CSF alone are the most common mobilization regimens for …
Long-term follow up of patients proceeding to transplant using plerixafor mobilized stem cells and incidence of secondary myelodysplastic syndrome/AML
We report the long-term follow up of 49 patients (pts) enrolled on plerixafor compassionate
use protocol. Thirty-seven pts (76%) had failed one previous mobilization attempt, while 12 …
use protocol. Thirty-seven pts (76%) had failed one previous mobilization attempt, while 12 …